The 4G/4G genotype at nucleotide position −675 in the promotor region of the plasminogen activator inhibitor 1 (PAI‐1) gene is less frequent in young patients with minor stroke than in controls

Genetic risk factors play an important role in the aetiology of vascular diseases. The insertion/deletion polymorphism (4G/5G) in the promotor region of the plasminogen activator inhibitor 1 (PAI‐1) gene has been associated with an increased risk of myocardial infarction. We investigated 136 patients with minor stroke (MS) and transient ischaemic attack (TIA) and found a prevalence of 0·32 for the 4G/4G genotype in patients compared with 0·42 in 115 age‐matched healthy controls. The 4G/4G genotype was significantly less frequent among 61 patients symptomatic before the age of 60 years (prevalence 0·20) than in 75 patients symptomatic after 60 years of age (prevalence 0·42; odds ratio). Our results indicate that the 4G/4G genotype is not a risk factor for MS or TIA and may even be protective in young patients.

[1]  D. Grobbee,et al.  Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. , 2000, Circulation.

[2]  J. Gilabert,et al.  Plasminogen Activator Inhibitor-1 (PAI-1) Promoter 4G/5G Genotype and Increased PAI-1 Circulating Levels in Postmenopausal Women with Coronary Artery Disease , 1999, Thrombosis and Haemostasis.

[3]  B. Wiman,et al.  4G/5G Polymorphism of PAI-1 Gene Promoter and Fibrinolytic Capacity in Patients with Deep Vein Thrombosis , 1998, Thrombosis and Haemostasis.

[4]  F. Burzotta,et al.  The 4G/5G Polymorphism of PAI-1 Promoter Gene and the Risk of Myocardial Infarction: A Meta-analysis , 1998, Thrombosis and Haemostasis.

[5]  A. Carter,et al.  Fibrinolytic measurements in Type 2 diabetic patients with acute cerebral infarction , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[6]  A. Carter,et al.  Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G Promoter Polymorphism and Levels in Subjects with Cerebrovascular Disease , 1997, Thrombosis and Haemostasis.

[7]  N. Ossei-Gerning,et al.  Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[8]  P. Grant,et al.  Plasminogen Activator Inhibitor-1 (PAI-1) Promoter Polymorphism and Coronary Artery Disease in Non-Insulin-Dependent Diabetes , 1995, Thrombosis and Haemostasis.

[9]  A. Hamsten,et al.  Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Assmann,et al.  Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. , 1993, Nucleic acids research.

[11]  A. Henney,et al.  Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[12]  Robert A. Zimmerman,et al.  Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. , 1990, Stroke.